Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Franziska Guenther

Team Leader - Assay Development and Screening


Franziska earned her PhD in Neurophysiology from Friedrich-Alexander University of Erlangen-Nuernberg, in collaboration with King's College London, building on an academic background in Molecular Medicine and Cell & Molecular Biology.

From 2018, she spent five years as a postdoctoral scientist at the Alzheimer's Research UK Oxford Drug Discovery Institute (ODDI), where she developed assays for early-stage drug discovery.

She then spent two years in global innovation consulting, supporting research commercialisation, innovation interventions and implementation of policy frameworks.

In 2025, she returned to the ODDI to lead the Assay Development and Screening team, focusing on biochemical and biophysical high-throughput screening assays. Her team works to identify chemical compounds that validate novel targets in neurodegeneration and serve as potential leads for therapeutic development.

Franziska has a keen interest in the intersection of drug discovery and intellectual property law, particularly its impact on global medicine accessibility and interdisciplinary collaboration.